HC Wainwright Reduces Earnings Estimates for Opus Genetics

Opus Genetics, Inc. (NASDAQ:IRD) – HC Wainwright cut their FY2025 earnings estimates for shares of Opus Genetics in a report released on Tuesday, April 1st. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.09) per share for the year, down from their prior estimate of ($1.03). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.52) EPS and FY2028 earnings at ($0.22) EPS.

Separately, Jones Trading cut their target price on shares of Opus Genetics from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday.

Opus Genetics Stock Down 9.6 %

Shares of Opus Genetics stock opened at $0.89 on Thursday. Opus Genetics has a one year low of $0.81 and a one year high of $1.56. The stock has a 50 day moving average of $1.06. The stock has a market cap of $28.40 million, a PE ratio of -0.81 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Monday, March 31st. The company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.93). Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The company had revenue of $3.40 million for the quarter, compared to the consensus estimate of $11.10 million.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.